TURNING POINT THERAPEUTICS I's ticker is TPTX and the CUSIP is 90041T108. A total of 156 filers reported holding TURNING POINT THERAPEUTICS I in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $71,782,000 | -32.5% | 953,914 | -75.9% | 0.01% | -18.2% |
| Q1 2022 | $106,397,000 | -41.5% | 3,962,652 | +4.0% | 0.01% | -31.2% |
| Q4 2021 | $181,812,000 | -16.7% | 3,811,568 | +16.0% | 0.02% | -23.8% |
| Q3 2021 | $218,281,000 | -3.3% | 3,285,881 | +13.5% | 0.02% | 0.0% |
| Q2 2021 | $225,797,000 | -5.3% | 2,894,095 | +14.8% | 0.02% | -12.5% |
| Q1 2021 | $238,465,000 | -23.1% | 2,521,043 | -1.0% | 0.02% | -25.0% |
| Q4 2020 | $310,204,000 | +81.9% | 2,545,785 | +30.4% | 0.03% | +60.0% |
| Q3 2020 | $170,502,000 | +38.4% | 1,951,718 | +2.3% | 0.02% | +33.3% |
| Q2 2020 | $123,188,000 | +105.5% | 1,907,229 | +42.1% | 0.02% | +66.7% |
| Q1 2020 | $59,958,000 | -35.6% | 1,342,539 | -10.2% | 0.01% | -25.0% |
| Q4 2019 | $93,150,000 | +103.9% | 1,495,426 | +23.1% | 0.01% | +100.0% |
| Q3 2019 | $45,679,000 | +26.1% | 1,214,857 | +36.5% | 0.01% | +20.0% |
| Q2 2019 | $36,225,000 | – | 890,050 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 2,392,297 | $291,501,000 | 6.94% |
| Burrage Capital Management LLC | 72,484 | $8,832,000 | 6.73% |
| MPM BioImpact LLC | 617,372 | $75,226,000 | 6.50% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 113,541 | $13,816,000 | 3.77% |
| Orbimed Advisors | 2,745,327 | $334,518,000 | 2.93% |
| SECTORAL ASSET MANAGEMENT INC | 257,379 | $31,362,000 | 2.21% |
| Parkman Healthcare Partners LLC | 59,377 | $7,235,000 | 1.85% |
| Nicholas Investment Partners, LP | 183,676 | $22,381,000 | 1.73% |
| EMERALD ADVISERS, LLC | 357,038 | $43,505,000 | 1.44% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 336,173 | $40,963,000 | 1.42% |